Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.67 |
| ▸ | RAB9A | P51151 | 4/20 | 0.59 |
| ▸ | NPC1 | O15118 | 3/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | USP2 | O75604 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.56 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.56 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.56 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.56 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.56 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.56 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11621538 | 0.89 | MAPT (0.81) | MAPTRAB9ANPC1SMN1; SMN2MEN1 | |
| SCHEMBL3704980 | 0.86 | MAPT (0.68) | MAPTRAB9ANPC1SMN1; SMN2MEN1 | |
| SCHEMBL3955088 | 0.85 | MAPT (0.62) | MAPTRAB9ANPC1SMN1; SMN2MEN1 | |
| SCHEMBL8209389 | 0.85 | MAPT (0.67) | MAPTRAB9ANPC1SMN1; SMN2MEN1 | |
| SCHEMBL9827893 | 0.84 | MAPT (0.70) | MAPTRAB9ANPC1SMN1; SMN2MEN1 | |
| SCHEMBL5506646 | 0.83 | MAPT (0.75) | MAPTRAB9ANPC1SMN1; SMN2MEN1 | |
| Dimethylamine SCHEMBL10718780 | 0.83 | MAPT (0.64) | MAPTRAB9ANPC1SMN1; SMN2MEN1 | |
| SCHEMBL14066861 | 0.82 | MAPT (0.61) | MAPTRAB9ANPC1SMN1; SMN2MEN1 | |
| SCHEMBL5507892 | 0.82 | MAPT (0.69) | MAPTRAB9ANPC1SMN1; SMN2MEN1 | |
| SCHEMBL11087441 | 0.81 | HDAC1 (0.70) | MAPTRAB9ANPC1SMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101641338-A | Multifunctional small molecules as antiproliferative agents | CURIS INC US | 2010-02-03 | — | — | CN | disclosed |
| US-20080234355-A1 | DNA METHYL TRANSFERASE INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. | 2008-09-25 | — | — | US | disclosed |
| US-20080234355-A1 | DNA METHYL TRANSFERASE INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. | 2008-09-25 | — | — | US | disclosed |
| US-20080234355-A1 | DNA METHYL TRANSFERASE INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. | 2008-09-25 | — | — | US | disclosed |
| US-20080221132-A1 | Multi-Functional Small Molecules as Anti-Proliferative Agents | CURIS, INC. | 2008-09-11 | — | — | US | disclosed |
| US-20080221132-A1 | Multi-Functional Small Molecules as Anti-Proliferative Agents | CURIS, INC. | 2008-09-11 | — | — | US | disclosed |
| WO-2008033747-A9 | MULTI-FUNCTIONAL SMALL MOLECULES AS ANTI-PROLIFERATIVE AGENTS | CURIS INC (MA) | 2008-07-24 | — | — | WO | disclosed |
| WO-2008033744-A2 | DNA METHYL TRANSFERASE INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
| WO-2008033747-A2 | MULTI-FUNCTIONAL SMALL MOLECULES AS ANTI-PROLIFERATIVE AGENTS | CURIS, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
| WO-2008033744-A2 | DNA METHYL TRANSFERASE INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
| EP-0285284-B1 | N-PHENETHYLAMINOALKYL-BENZAMIDE ANTI-ARRHYTHMIA AGENTS | Pfizer Limited (GB) | 1991-05-15 | — | — | EP | disclosed |
| EP-0285284-A2 | N-phenethylaminoalkyl-benzamide anti-arrhythmia agents | Pfizer Limited (GB) | 1988-10-05 | — | — | EP | disclosed |
| EP-0199042-A1 | Procainamide assay, tracers, immunogens and antibodies | ABBOTT LABORATORIES (US) | 1986-10-29 | — | — | EP | disclosed |
| US-4235969-A | IMMUNOASSAYS FOR DETERMINATION OF BENZAMIDES OF N,N-DIALKYLETHYLENEAMINES | SYVA COMPANY (US) | 1980-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234355-A1 | DNA METHYL TRANSFERASE INHIBITORS CONTAINING A ZINC BINDING MOIETY | DNMT1, DNMT3B, DNMT3A | MAPT 1735/4885RAB9A 3642/4885NPC1 1266/4885 |
| US-20080221132-A1 | Multi-Functional Small Molecules as Anti-Proliferative Agents | HDAC1, HDAC6, HDAC5 | MAPT 3758/4885RAB9A 3181/4885NPC1 3092/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.